Stock AnalizAnaptysbio, Inc. ANAB
Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026
Anaptysbio, Inc. (ANAB) is a healthcare company listed in the US with a market value of about $1.4B. In the twelve months to September 30, 2026 it had revenue of $192M and net income of $184M, a net margin of 96.3%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is future growth (4/5); the weakest is shareholder returns (1/5).
Key numbers: a P/E of 7.1, a price to free cash flow of 70.1, 5-year revenue growth of 26% a year, a 5-year average ROIC of 96%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 43% below the current price.
Score: 2.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- Profitable 5 years in a row
- ROE above 15%
- Liabilities below 60% of assets
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $192M | $235M | $91M | $17M | $10M | $63M | $75M | $8M | $5M | $10M | $17M |
| Net income | $184M | -$13M | -$145M | -$164M | -$129M | -$58M | -$20M | -$97M | -$62M | -$30M | -$4M |
| Free cash flow | — | $20M | -$136M | -$122M | -$74M | -$47M | -$15M | -$70M | -$50M | -$20M | -$9M |
| EPS (diluted) | $5.33 | $-0.44 | $-4.92 | $-6.08 | $-4.57 | $-2.11 | $-0.73 | $-3.60 | $-2.50 | $-1.52 | $-1.62 |
| Net margin | 96.3% | -5.6% | -159.1% | -953.7% | -1251.3% | -91.5% | -26.6% | -1216.7% | -1233.1% | -300.7% | -25.5% |
| ROIC | — | 606.7% | 75.7% | -155.2% | -32.3% | -15.0% | -6.0% | -26.3% | -13.4% | -9.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $87.25, 89% above the current price; targets range from $60.00 to $140.00; the consensus rating is “Strong buy”; expected EPS is $3.24 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Anaptysbio’s P/E ratio?
About 7.1, based on the last twelve months of diluted earnings per share (forward P/E about 10.3).
Is Anaptysbio stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 43% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Anaptysbio pay a dividend?
Not currently.
Is Anaptysbio a good stock to buy?
We do not give buy or sell advice. Anaptysbio scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.